Table 1 Clinical characteristics of all patients stratified by age
Variables | Total | 35–50 y | 51–74 y | ≥75 y | P-value |
|---|---|---|---|---|---|
Number of patients | 102 | 11 | 57 | 34 | – |
 Male, n (%) | 73 (71.6 %) | 11 (100 %) | 46 (80.7 %) | 16 (47.1 %) | <0.001 |
 Age (years) | 69 (56–77) | 42 (38–49) | 64 (56–70) | 79 (77–84) | <0.001 |
 Body mass index (kg/m2) | 24 (22–25) | 26 (25–29)*,††| 24 (21–26) | 22 (20–24) | <0.01 |
 Triglycerides (mg/dL) | 111 (67–171) | 143 (132–194) | 110 (63–177) | 95 (66–129) | 0.09 |
 HDL-C (mg/dL) | 45 (39–59) | 42 (34–43)* | 47 (40–60) | 45 (38–60) | 0.04 |
 LDL-C (mg/dL) | 114 (92–137) | 133 (101–185) | 113 (90–132) | 117 (84–148) | 0.09 |
 HbA1c (%) | 5.9 (5.6–6.4) | 5.8 (5.4–6.7) | 6.0 (5.5–6.6) | 5.9 (5.6–6.4) | 0.53 |
Fatty acid concentrations | |||||
 EPA (μg/mL) | 43 (29–65) | 28 (21–55)*,†| 43 (34–65) | 46 (30–69) | 0.12 |
 DHA (μg/mL) | 119 (97–149) | 102 (94–140) | 118 (97–150) | 125 (97–163) | 0.36 |
 AA (μg/mL) | 165 (141–206) | 193 (164–234) | 167 (152–203) | 143 (126–211) | 0.09 |
 EPA/AA | 0.25 (0.17–0.37) | 0.17 (0.07–0.23)*,†| 0.26 (0.18–0.37) | 0.29 (0.19–0.42) | 0.03 |
 DHA/AA | 0.75 (0.59–0.96) | 0.70 (0.47–0.89) | 0.67 (0.56–0.95) | 0.83 (0.70–1.00) | 0.05 |
Complications | |||||
 Dyslipidemia, n (%) | 38 (37 %) | 6 (55 %) | 22 (39 %) | 10 (29 %) | 0.31 |
 Hypertension, n (%) | 63 (62 %) | 5 (45 %) | 34 (60 %) | 24 (71 %) | 0.29 |
 Diabetes mellitus, n (%) | 29 (28 %) | 2 (18 %) | 19 (33 %) | 8 (24 %) | 0.44 |
 Current smoking, n (%) | 44 (43 %) | 9 (82 %) | 28 (49 %) | 7 (21 %) | <0.01 |
Drugs | |||||
 ACEI/ARB, n (%) | 27 (26 %) | 1 (9 %) | 11 (19 %) | 15 (44 %) | 0.01 |
 β-blockers, n (%) | 10 (10 %) | 1 (9 %) | 4 (7 %) | 5 (15 %) | 0.49 |
 Calcium channel blockers, n (%) | 27 (26 %) | 1 (9 %) | 15 (26 %) | 11 (32 %) | 0.31 |
 Statins, n (%) | 15 (15 %) | 2 (18 %) | 11 (19 %) | 2 (6 %) | 0.20 |
 Aspirin, n (%) | 16 (16 %) | 2 (18 %) | 8 (14 %) | 6 (18 %) | 0.28 |